![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Senseonics Holdings Inc | AMEX:SENS | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.0041 | 1.06% | 0.3891 | 0.3955 | 0.3829 | 0.389 | 1,258,058 | 19:18:31 |
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.
Management is scheduled to participate on Wednesday, March 13, 2024, at 12:00pm ET and will hold one-on-one meetings following. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306655647/en/
Senseonics Investor Contact Philip Taylor Gilmartin Group 415-937-5406 Investors@senseonics.com
1 Year Senseonics Chart |
1 Month Senseonics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions